Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15104993 | 0.87 | C5AR1 (0.35) | C5AR1HTR2AHTR2CHTR2B | |
| SCHEMBL15104992 | 0.87 | C5AR1 (0.35) | C5AR1HTR2AHTR2CHTR2B | |
| SCHEMBL14671820 | 0.73 | TNKS (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL3727019 | 0.66 | HTR2A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL14483941 | 0.66 | HTR2A (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL19711550 | 0.63 | HTR2A (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL12706725 | 0.63 | HTR2A (0.49) | HTR2AHTR2CHTR2B | |
| SCHEMBL13329582 | 0.63 | HTR2C (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL29380880 | 0.63 | HTR2A (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL14660670 | 0.61 | C5AR1 (0.37) | C5AR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505755-B2 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20140349995-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-8846656-B2 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20130184253-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349995-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | C5AR1 1/4885HTR2A 361/4885HTR2C 386/4885 |
| US-20130184253-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | C5AR1 1/4885HTR2A 310/4885HTR2C 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.